In this issue:
Thrombopoietin: a bone marrow failure marker in myelodysplastic syndromes
Impact of age on CALGB
CLL study outcomes
Salvage lenalidomide and rituximab in relapsed/refractory CLL
Risk of therapy-related secondary leukaemia in HL
ABVD vs. Stanford V in adva
Please login below to download this issue (PDF)